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We investigated the thermostability at 41 “C of human plasma cu-mannosidase in two cystic fibrosis 
patients, one carrier, and two healthy adults. We could not confirm the reported ifferences between these 
groups of subjects. 
Human disease Cystic fibrosis Pathogenetic mechanism Lysosomal enzyme a4fannosidase 
1. INTRODUCTION several occasions. The mother of patient no. 1 and 
both controls were apparently healthy. 
The molecular defect in cystic fibrosis (CF), the 
most common lethal inherited disease of whites 
[l], is unknown. One of the many metabolic ab- 
normalities observed in the disease [2,3] seems to 
affect lysosomal enzymes. One of them, an acid cy- 
mannosidase, was reported to show a decreased 
thermostability in patients and, to a lesser degree, 
in carriers, suggesting a close relation to the basic 
defect [4]. Because of the potential interest of these 
investigations for understanding the pathogenesis 
of CF, and since our laboratory routinely deals 
with lysosomal enzyme deficiencies, we repeated 
the cY-mannosidase thermolability studies in 
plasma from patients cared for at our own 
institution. 
Blood sampling, preparation of plasma, heat in- 
activation, and measurement of cY-mannosidase ac- 
tivity with a fluorogenic substrate were done exact- 
ly as in [4], following all the precautions mention- 
ed. Experience with some delicate aspects of the 
procedures was gathered in preliminary ex- 
periments, until reproducible results were 
obtained. 
3. RESULTS 
Residual activity of plasma a-mannosidase after 
various lengths of incubation at 41°C is shown in 
table 1. A difference that would distinguish pa- 
tients or carriers from controls was not detectable. 
2. SUBJECTS AND METHODS 4. DISCUSSION 
Patient no.1 was a 2-month-old boy suffering 
from meconium ileus and pneumonias. After his 
death a few weeks after the study, the diagnosis of 
CF was confirmed by histological examination of 
the pancreas. Patient no.2 was a lZyear-old boy 
with typical severe pulmonary changes and pan- 
creatic insufficiency. [NaCl] in sweat was elevated 
to levels diagnostic for CF in both patients on 
Abbreviation: CF, cystic fibrosis 
Our inability to confirm an abnormal ther- 
molability of a-mannosidase activity in plasma of 
CF-patients adds to a long list of observations in 
CF that have been difficult to reproduce in other 
laboratories [2,3]. Contradicting results of cy- 
mannosidase thermostability in different 
laboratories can be explained in the following 
ways: 
(i) Technical details have not been standardized 
sufficiently; e.g., some types of plastic tubes 
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Table 1 
Heat-inactivation at 41°C of a-mannosidase in plasma 
from two CF-patients, one carrier and two controls 
Subjects Time of inactivation (min) 
40 80 120 160 200 240 
Patient no. 1 
(age 2 months) 83 79 79 72 65 69 
Patient no.2 
(age 12 years) 100 98 98 84 85 85 
Mother of patient 
no.1 86 80 75 67 69 66 
Control no. 1 
(adult) 77 80 76 73 71 58 
Control no.2 
(adult) 72 76 76 66 69 60 
Residual enzyme activity in % of activity without 
heat-inactivation 
appear to be toxic (P. Hosli, personal 
communication); 
(ii) cr-Mannosidase thermolability is not very 
closely related to the basic defect in CF; 
(iii) Genetic heterogeneity of CF is possible. 
Since investigation of lysosomal abnormalities 
may yield potentially valuable information for 
understanding CF, we suggest hat workers willing 
to reproduce studies of the kind referred to in this 
paper address directly to the laboratory where the 
original work was done. 
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